Processing Magazine

Regeneron Sees Progress with Two Drug Candidates

May 13, 2010
Regeneron Pharmaceuticals Inc. said Wednesday early stage testing showed that one of its drug candidates lowered cholesterol levels, and mid-stage testing on a potential pain reliever showed it was well-tolerated, according to the Associated Press. The company said a cholesterol drug candidate labeled REGN727 achieved "substantial" decreases in low-density lipoprotein, or LDL, cholesterol at certain doses. It will present more information at its investor day July 15 in New York. Regeneron also said a pain reliever labeled REGN475 was "generally well tolerated" by patients. It showed improvements in walking pain when studied in 217 patients with osteoarthritis of the knee.